Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE: Little is known about the progression of dopaminergic dysfunction in LRRK2-associated Parkinson disease (PD). We sought to characterize the neurochemical progression with multitracer PET in asymptomatic members of parkinsonian kindred (family D, Western Nebraska) carrying LRRK2 (R1441C) mutation. METHOD: Thirteen family D subjects underwent PET scans of presynaptic dopaminergic integrity and five subjects were rescanned 2 to 3 years later. RESULTS: In subjects 8, 9 (mutation carriers), and 13 (genealogically at risk subject), there was a decline in PET markers over the course of the study that was significantly greater than the expected rate of decline in healthy controls. Reduced dopamine transporter binding was the earliest indication of subclinical dopaminergic dysfunction and progression to clinical disease was generally associated with the emergence of abnormal fluorodopa uptake. CONCLUSION: PET study of presymptomatic members of our LRRK2 kindred revealed dopaminergic dysfunction that progressed over time. This represents an ideal group to study the natural history of early disease and the potential effects of neuroprotective interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Li, X., Patel, J. C., Wang, J., Avshalumov, M. V., Nicholson, C., Buxbaum, J. D., Elder, G. A., Rice, M. E., & Yue, Z. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5604-09.2010 · Cited by 341
Melrose, H. L., Dächsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., Kent, C. B., Korvatska, E., Taylor, J. P., Witten, L., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.010 · Cited by 275
Self-citationImpaired dopamine release in Parkinson’s disease
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023) · Brain · doi:10.1093/brain/awad064 · Cited by 207
“Studies demonstrate that in asymptomatic Y1699C and R1441C leucine-rich repeat kinase 2 (LRRK2) mutation carriers, (18)F-DOPA uptake was normal, despite evidence for impaired DA function with abnormal DAT binding.(27,31) A longitudinal study that followed asymptomatic LRRK2 G2019S carriers who went on to convert to Pa…”
BackgroundResultLRRK2 in Parkinson’s disease: genetic and clinical studies from patients
Kumari, U., & Tan, E. K. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07344.x · Cited by 125
Metadata
- Authors
- Nandhagopal, R., Mak, E., Schulzer, M., McKenzie, J., McCormick, S., Sossi, V., Ruth, T. J., Strongosky, A., Farrer, M. J., Wszolek, Z. K., & Stoessl, A. J.
- Venue
- Neurology
- Published
- 2008-11-25
- Volume
- 71
- Issue
- 22
- Pages
- 1790-1795
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2085740388
- Cited by
- 120
- References
- 0
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study. https://app.cochat.ai/papers/10.1212/01.wnl.0000335973.66333.58
- The paper
- Nandhagopal, R., Mak, E., Schulzer, M., McKenzie, J., McCormick, S., Sossi, V., Ruth, T. J., Strongosky, A., Farrer, M. J., Wszolek, Z. K., & Stoessl, A. J. (2008). Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study. Neurology. https://doi.org/10.1212/01.wnl.0000335973.66333.58
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.